Burtness B - Search Results

1

Targeted agents: management of dermatologic toxicities.

Burtness B. Burtness B. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):793-6. doi: 10.6004/jnccn.2014.0192. J Natl Compr Canc Netw. 2014. PMID: 24853219

2

NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.

Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. Burtness B, et al. J Natl Compr Canc Netw. 2009 May;7 Suppl 1:S5-21; quiz S22-4. doi: 10.6004/jnccn.2009.0074. J Natl Compr Canc Netw. 2009. PMID: 19470276 Review.

3

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA. Mehra R, et al. Among authors: burtness b. Drug Resist Updat. 2011 Dec;14(6):260-79. doi: 10.1016/j.drup.2011.08.002. Epub 2011 Sep 14. Drug Resist Updat. 2011. PMID: 21920801 Free PMC article. Review.

4

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.

Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Burtness B, et al. Trials. 2014 Nov 29;15:469. doi: 10.1186/1745-6215-15-469. Trials. 2014. PMID: 25432788 Free PMC article. Clinical Trial.

5

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B. Burtness B. Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. doi: 10.1517/14712598.5.8.1085. Expert Opin Biol Ther. 2005. PMID: 16050785 Review.

6

Images in clinical medicine. Cetuximab-associated acneiform eruption.

Moss JE, Burtness B. Moss JE, et al. Among authors: burtness b. N Engl J Med. 2005 Nov 10;353(19):e17. doi: 10.1056/NEJMicm050560. N Engl J Med. 2005. PMID: 16282170 Free article. No abstract available.

7

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Burtness B, et al. J Clin Oncol. 2005 Dec 1;23(34):8646-54. doi: 10.1200/JCO.2005.02.4646. J Clin Oncol. 2005. PMID: 16314626 Clinical Trial.

8

Her signaling in pancreatic cancer.

Burtness B. Burtness B. Expert Opin Biol Ther. 2007 Jun;7(6):823-9. doi: 10.1517/14712598.7.6.823. Expert Opin Biol Ther. 2007. PMID: 17555368 Review.

9

Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.

Burtness B. Burtness B. Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7. Oncology (Williston Park). 2007. PMID: 17715697 Free article. Review.

10

Targeting EGFR resistance networks in head and neck cancer.

Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Ratushny V, et al. Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Epub 2009 Mar 1. Cell Signal. 2009. PMID: 19258037 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page